Beijing Jingxuan Law Firm Legal Opinion on the 2025 Annual General Meeting of Harbin Honor Pharmaceutical Co., Ltd.
To Harbin Honor Pharmaceutical Co., Ltd.:
Pursuant to the "Company Law of the People's Republic of China" (hereinafter referred to as the "Company Law"), the "Securities Law of the People's Republic of China" (hereinafter referred to as the "Securities Law"), the "Rules for Shareholders' Meetings of Listed Companies" issued by the China Securities Regulatory Commission (hereinafter referred to as the "Shareholders' Meeting Rules"), and other relevant laws, regulations, and normative documents, as well as the "Articles of Association of Harbin Honor Pharmaceutical Co., Ltd." (hereinafter referred to as the "Articles of Association"), Beijing Jingxuan Law Firm (hereinafter referred to as "this Firm") was entrusted by Harbin Honor Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") to appoint lawyers to attend the Company's 2025 Annual General Meeting and issue this legal opinion on relevant matters.
To issue this legal opinion, the lawyers appointed by this Firm attended the Company's general meeting and reviewed the relevant documents and materials provided by the Company for the convening of this general meeting. The lawyers of this Firm hereby state:
- The Company shall be responsible for the truthfulness, completeness, and validity of the meeting materials and other relevant information provided to the lawyers of this Firm for this general meeting (including but not limited to board resolutions, announcements on the convening of this general meeting, the shareholder register for the stock registration date of this general meeting, etc.).